

Anti-TNFRSF10B / TRAILR2 / CD262 Reference Antibody (tigatuzumab)

Recombinant Antibody
Catalog # APR10601

Product Information

Application	FC, Kinetics, Animal Model
Primary Accession	O14763
Reactivity	Human
Clonality	Monoclonal
Isotype	IgG1
Calculated MW	47878


Additional Information

Target/Specificity	TNFRSF10B / TRAILR2 / CD262
Endotoxin Conjugation	Unconjugated
Expression system	CHO Cell
Format	Purified monoclonal antibody supplied in PBS, pH6.0, without preservative. This antibody is purified through a protein A column.


Protein Information

Name	TNFRSF10B
Synonyms	DR5, KILLER, TRAILR2, TRICK2, ZTNFR9
Function	Receptor for the cytotoxic ligand TNFSF10/TRAIL (PubMed: 10549288). The adapter molecule FADD recruits caspase-8 to the activated receptor. The resulting death-inducing signaling complex (DISC) performs caspase-8 proteolytic activation which initiates the subsequent cascade of caspases (aspartate-specific cysteine proteases) mediating apoptosis. Promotes the activation of NF-kappa-B. Essential for ER stress-induced apoptosis.
Cellular Location	Membrane; Single-pass type I membrane protein.
Tissue Location	Widely expressed in adult and fetal tissues; very highly expressed in tumor cell lines such as HeLaS3, K-562, HL-60, SW480, A-549 and G-361; highly expressed in heart, peripheral blood lymphocytes, liver, pancreas, spleen, thymus, prostate, ovary, uterus, placenta, testis, esophagus, stomach and throughout the intestinal tract; not detectable in brain

Images



Anti-TNFRSF10B / TRAILR2 / CD262 Reference Antibody (tigatuzumab) on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 90%



The purity of Anti-TNFRSF10B / TRAILR2 / CD262 Reference Antibody (tigatuzumab) is more than 95%, determined by SEC-HPLC.

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.